Clinicopathologic and Prognostic Significance of Body Mass Index (BMI) among Breast Cancer Patients in Western China: A Retrospective Multicenter Cohort Based on Western China Clinical Cooperation Group (WCCCG)
Table 6
Subgroup analyses of DFS according to breast cancer patients with BMI categories.
Subgroup
BMI at diagnosis for patients (kg/m2)
<18.5
18.5-24.9
25-29.9
HR (95% CI) †
P
HR (95% CI)
P
HR (95% CI) †
P
Overall
2.80 (1.66, 4.73)
<0.001
Reference
1.40 (1.05, 1.88)
0.02
Age (year)
<35
5.68 (1.38, 23.39)
0.02
Reference
3.72 (0.91, 15.27)
0.07
35-60
3.62 (1.80, 7.31)
<0.001
Reference
1.65 (1.16, 2.35)
0.01
>60
2.84 (0.33, 24.25)
0.34
Reference
1.03 (0.46, 2.33)
0.94
Menopausal status
Premenopausal
1.99 (1.01, 3.95)
0.04
Reference
1.34 (0.87, 2.06)
0.18
Postmenopausal
7.03 (2.97, 16.63)
<0.001
Reference
1.63 (1.06, 2.50)
0.03
Tumor size (cm)
<2
7.67 (1.66, 35.35)
0.01
Reference
2.39 (0.79, 7.24)
0.13
2-5
2.95 (1.48, 5.87)
0.002
Reference
1.46 (1.01, 2.12)
0.04
>5
3.05 (0.90, 10.42)
0.08
Reference
1.32 (0.73, 2.40)
0.36
ALN metastasis
No
5.12 (2.44, 10.74)
<0.001
Reference
2.15 (1.21, 3.79)
0.01
Yes
1.60 (0.67, 3.80)
0.29
Reference
1.30 (0.91, 1.84)
0.15
Nuclear grade
I/ II
4.86 (2.61, 9.05)
<0.001
Reference
1.31 (0.89, 1.92)
0.17
III
1.72 (0.62, 4.83)
0.30
Reference
1.48 (0.90, 2.42)
0.12
Subtype
Luminal-like
4.91 (1.82, 13.26)
0.002
Reference
0.93 (0.52, 1.68)
0.82
HER2/luminal-like
3.34 (0.75, 14.81)
0.11
Reference
2.14 (1.23, 3.75)
0.01
HER2-like
6.86 (2.36, 19.90)
<0.001
Reference
1.25 (0.65, 2.39)
0.51
TNBC
0.83 (0.22, 3.11)
0.78
Reference
2.33 (1.06, 5.12)
0.04
Chemotherapy
No
6.40 (1.35, 30.41)
0.02
Reference
1.03 (0.32, 3.28)
0.97
Yes
2.66 (1.50, 4.73)
0.001
Reference
1.48 (1.09, 2.02)
0.01
Disease-free survival (DFS) was defined as the time from surgery to the date of the first locoregional recurrence, first distant metastasis, or death from any cause. † Multivariate analysis adjusted by BMI, age at diagnosis, tumor size, number of positive ALN, nuclear grade, status of ER, PR, and HER2, surgery, chemotherapy, endocrine therapy, and radiotherapy. HR, hazard ratio; CI, confidence intervals; ALN, axillary lymph nodes.
